EFFECTS OF GROWTH HORMONE THERAPY ON BODY COMPOSITION AND LIPID KINETICS IN SUBJECTS WITH HIV LIPODYSTROPHY SYNDROME:
INCLUSION CRITERIA:
HIV-seropositive patients with a clinical diagnosis of lipodystrophy (N=10)
Adults greater than or equal to 18 yr
EXCLUSION CRITERIA:
Prior history of diabetes
Hypothyroidism, hyperthyroidism
Hypercortisolism
Hypogonadism
Concomittant acute or chronic illness
Concurrent treatment with medications known to interfere with insulin secretion or action
Concurrent treatment with lipid lowering agents
Transaminasemia greater than or equal to 2X upper limits of normal
Creatinine clearance less than 50 ml/min
History of pancreatitis associated with hypertriglyceridemia
History of cancer, acromegaly, or pituitary tumor
History of cardiovascular disease (myocardial infarction, cerebrovascular accident, angina)
PATHOGENESIS OF HIV-ASSOCIATED LIPODYSTROPHY SYNDROME: ROLE OF HIV VIRAL PROTEINS:
INCLUSION CRITERIA:
HIV-1 seropositive patients (N=10) and healthy, HIV seronegative volunteers (N=10)
Adults greater than 18 yr
EXCLUSION CRITERIA:
Treatment with glucocorticoids for greater than 2 weeks during the preceding 6 months
Diabetes Mellitus
Pregnancy
Menopause
Hypopituitarism, primary hypothyroidism, primary hypogonadism, or treatment with anabolic agents
Abnormal liver function
Abnormal renal function
Active drug or alcohol abuse
Chronic illness other than HIV
BMI less than 23 or greater than 32